US pharma major AbbVie saw its shares drop 4.5% to $218.04 by close of trading on Friday, despite reporting financial results for the third quarter ended September 30, 2025, that beat expectation.

The European Medicines Agency’s Pharmacovigilance Risk Committee (PRAC) has agreed on a direct healthcare professional communication (DHPC) to remind healthcare professionals that extreme caution ...

South Korea-based Celltrion today announced that the US Food and Drug Administration (FDA) has designated Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) as interchangeable biosimilars to the ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) has begun in-house manufacturing and clinical use of CAR-T cell ...

US anti-virals giant Gilead Sciences late yesterday announced its third quarter 2025 results of operations, reporting total ...

An Austrian biotech company developing protein-conjugation technologies aimed at accelerating vaccine and therapeutic ...

US biotech 4D Molecular Therapeutics (Nasdaq: FDMT) has granted Japan’s Otsuka Pharmaceutical (TYO: 4578) exclusive rights to ...

German family-owned pharma major Boehringer Ingelheim has licensed a pre-clinical program from Japan’s Kyowa Kirin to develop ...

The top 20 global biopharmaceutical companies saw their combined market capitalization rise 4% in the third quarter of 2025 ...

The US Health Resources and Services Administration (HRSA) has approved nine drugs for a pilot testing a new rebate model ...

China’s R&D and manufacturing services provider WuXi AppTec has reached agreement for Hillhouse Investment Management to ...

Swiss pharma major Roche (ROG: SIX) has entered a global exclusive licensing agreement with China’s Qyuns Therapeutics for ...